Skip to main content

Advertisement

Table 2 Efficacy of anti-TNFα drugs on ACR20, ACR50 and ACR70 responses

From: Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety

Trial (reference) Comparisons Duration of trial in months Groups N of patients 6 month ACR20 6 month ACR50 6 month ACR70 12 month ACR20 12 month ACR50 12 month ACR70 24 month ACR20 24 month ACR50 24 month ACR70
Lipsky et al. (19) Infliximab+MTX vs. MTX 12 months 3 mg/Kg 8 wk +MTX* 86   22/86 7/86 36/86 18/86 9/86    
  3 mg/Kg 4 wk +MTX 86 43/86 25/86 9/86 41/86 29/86 31/86    
  10 mg/Kg 8 wk +MTX 87 43/86 27/87 15/87 51/87 34/87 22/87    
  10 mg/Kg 4 wk +MTX 81 45/87 21/81 9/81 48/81 31/81 15/81    
  Total Infliximab 340 47/81 95/340 40/340 176/340 112/340 77/340    
  MTX 88 178/340 4/88 0/88 15/88 7/88 2/88    
  Total 428 18/88         
St. Clair et al. (20) Infliximab+MTX vs. MTX 12 months 3 mg/Kg 8 wk +MTX* 373   NA NA 231/373 171/373 123/373    
  6 mg/Kg 8 wk +MTX 378     249/378 189/378 140/378    
  Total Infliximab 751 NA    480/751 360/751 263/751    
  MTX 298     161/298 95/298 62/298    
  Total 1049          
Quinn et al. (22) Infliximab+MTX vs. MTX 12 months 3 mg/Kg 8 wk +MTX* 10     8/10 8/10 7/10    
  MTX 10 NA NA NA 6/10 4/10 3/10    
  Total 20          
Westhovens et al. (23) Infliximab+MTX vs. MTX 6 months 3 mg/Kg 8 wk +MTX* 360   110/360 48/360       
  10 mg/Kg 8 wk +MTX 361 199/360 119/361 54/341       
  Total Infliximab 721 205/361 229/721 102/721       
  MTX 363 404/721 33/363 16/363       
  Total 1084 87/363         
oreland et al. (24) Etanercept vs. placebo 6 months 25 mg 2 twice weekly * 78   31/78 11/78       
  10 mg 2 twice weekly 76 46/78 18/76 7/76       
  Total Etanercept 154 37/76 49/154 18/154       
  Placebo 80 83/154 4/80 1/80       
  Total 234 9/80         
Weinblatt et al. (25) Etanercept+MTX vs. MTX 6 months 25 mg 2 +MTX * 59 42/59 23/59 9/59       
  MTX 30 8/30 1/30 0/30       
  Total 89          
Bathon et al. (26) ** Etanercept vs. MTX 12 months 25 mg 2 twice weekly * 207 147/207 NA NA 149/207 101/207 52/207    
  10 mg 2 twice weekly 208 NA NA NA NA NA NA    
  Total Etanercept 415 56/217 NA NA 141/217 93/217 47/217    
  MTX 217          
  Total 632          
van der Heijde et al. (28) (TEMPO) Etanercept+MTX vs. etanercept vs MTX 24 months 25 mg 2 twice weekly +MTX * 231 NA NA NA 196/231 159/231 99/231 199/231 164/231 113/231
  25 mg 2 twice weekly* 223     169/223 107/223 54/223 167/223 120/223 60/223
  Total Etanercept 454     365/454 266/454 153/454 386/454 284/454 173/454
  MTX 228     171/228 98/228 43/228 162/228 96/228 4/228
  Total 682          
Weinblatt et al. (29) ARMADA) dalimumab+MTX vs. MTX 6 months 40 mg/2 s+MTX* 67 45/67 37/67 18/67       
  20 mg/2 s+MTX 69 33/69 22/69 7/69       
  80 mg/2 s+MTX 73 48/73 31/73 14/73       
  Total Adalimumab 209 126/209 90/209 39/209       
  MTX 62 9/62 5/62 3/62       
  Total 271          
van de Putte et al. (30) Adalimumab vs. Placebo 6 months 40 mg/2 wk * 113   25/113 14/113       
  20 mg/2 wk 106 52/113 20/106 9/106       
  20 mg/wk 112 38/106 23/112 11/112       
  40 mg/wk 103 44/112 36/103 19/103       
  Total Adalimumab 434 55/103 104/434 53/434       
  Placebo 110 189/434 9/110 2/110       
  Total 544 21/110         
Furst et al. (31) (STAR) Adalimumab+DAMAR D vs. DAMARD 6 months 40 mg/2 wk * 318   93/318 47/318       
  DMARD 318 169/318 35/318 10/318       
  Total 636 111/318         
Keystone et al. (32) Adalimumab+MTX vs. MTX 12 months 40 mg/2 wk +MTX* 207 131/207 80/207 43/207 122/207 86/207 48/207    
  20 mg/wk +MTX 212 129/212 87/212 36/212 116/212 80/212 44/212    
  Total Adalimumab 419 260/419 167/419 79/419 238/419 166/419 92/419    
  MTX 200 59/200 19/200 5/200 48/200 19/200 9/200    
  Total 619          
Breedveld et al. (33) (PREMIER) Adalimumab+MTX vs. adalimumab vs MTX 24 months 40 mg/2 wk+MTX* 268 NA NA NA 196/268 166/268 123/268 185/268 158/268 126/268
  40 mg/2 wk * 274     148/274 112/274 71/274 134/274 101/274 77/274
  Total Adalimumab 542     344/542 278/542 194/542 319/542 259/542 203/542
  MTX 257     162/257 118/257 72/257 144/257 111/257 72/257
  1. * groups receiving doses currently recommended
  2. NA: not available